In this episode of the Lupus Foundation of America's The Expert Series podcast, we focus on managing lupus when access to a rheumatologist is limited, including regular testing, medication management, ...

Purple for a Purpose partner and Inspira founder Rachel shares about her mom's journey with lupus and how it inspired her ...

New research is shedding light on the biological mechanisms that may help explain why systemic lupus erthyematosus (SLE) and other autoimmune diseases are more common in women. Two studies from the ...

Yesterday, the House Appropriations Committee approved the Fiscal Year 2027 Defense Appropriations bill, which includes $10 million for the Department of Defense (DoD) Lupus Research Program (LRP). In ...

In a new study, researchers found achieving low disease activity or remission is possible and meaningful for people with lupus nephritis, (LN, lupus-related kidney disease) once their kidneys start ...

June is Men’s Health Month, a time to shine light on the health challenges that affect men with lupus and encourage open, honest conversations about care and well-being. For the lupus community, this ...

The U.S. Food & Drug Administration (FDA) has granted approval for subcutaneous administration of anifrolumab (SAPHNELO) for treatment of people living with moderately to severely active ...

Join us for this webinar to learn how lupus can affect the central nervous system (CNS), including neuropsychiatric lupus (NPSLE) and gain a better understanding of common NPSLE symptoms. We’ll also ...

The U.S. Food and Drug Administration (FDA) has granted Johnson & Johnson’s, nipocalimab, Fast Track designation as a potential treatment for adults with systemic lupus erythematosus (SLE). This ...

Individuals and families in need can access short-term financial assistance and local resources to help cover basic expenses or emergencies. Programs like Findhelp and Modest Needs provide support for ...

A new study exploring the investigational therapy, Zorpo-cel, met its primary safety and secondary efficacy endpoints in people with progressive and treatment-resistant systemic sclerosis (SSc), ...

The U.S. Food and Drug Administration (FDA) issued a complete response letter requesting additional information from AstraZeneca regarding the Biologics License Application (BLA) for subcutaneous (SC) ...